Abstract
Endometriosis is a common yet often underdiagnosed condition, partly due to the lack of reliable diagnostics. This study examines the clinical feasibility of a blood-based, miRNA-driven test to diagnose endometriosis and address the challenges of translating next-generation sequencing (NGS) findings into clinical use. Serum from 20 patients and 20 controls underwent miRNA sequencing to identify diagnostic biomarkers. A machine learning model built on all NGS-based differentially expressed miRNA biomarkers achieved ≥90% accuracy. Validation by qPCR confirmed some but not all findings, underscoring the difficulty of adapting NGS discoveries for routine diagnostics. Nonetheless, serum miRNA biomarkers show strong promise for non-invasive endometriosis detection, with further optimization needed for clinical translation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by internal R&D budget of HerAnova Lifesciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The participants were enrolled under an approved institutional review board protocol (IRB-20240110-R) at the Womens Hospital of Zhejiang University School of Medicine, with informed consent obtained from all individuals
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
